FDA
-
-
-
-
-
-
-
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
-
-
-
-
-
-
-
Plus Therapeutics (PSTV) Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ
-
-
-
-
-
-
-
Plus Therapeutics (PSTV) Says REYOBIQ Showed Clinical Benefit and Safety in the ReSPECT-LM Trial
-
-
-
-
-
-
-
Plus Therapeutics (PSTV) Announces Publication Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
-
-
-
-
-
-
-
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
-
-
-
-
-
-
-
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
-
-
-
-
-
-
-
Plus Therapeutics (PSTV) and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

